CCR

CC chemokine receptor (CCR) antagonists block G protein-coupled receptors that guide leukocyte migration. CCR2, a receptor for monocyte chemoattractant protein 1 (MCP-1), was cloned in 1994 as two splice variants. CCR5 was identified in 1996 as a fusion cofactor for macrophage-tropic human immunodeficiency virus type 1 (HIV-1). Maraviroc, described in 2005 as a selective small-molecule CCR5 inhibitor, blocks this route of viral entry. Other CCR5 antagonists include vicriviroc malate and aplaviroc, while INCB3344 and MK-0812 target CCR2. Cenicriviroc blocks both CCR2 and CCR5, and GSK2239633A is a CCR4 antagonist for studies of T cell trafficking.

Items 51-75 of 154

  • CCR5 antagonist 2
    Cat. No.
    A51535

    CCR5 antagonist 2

    CCR5 antagonist 2 is a potent inhibitor of the CCR5 receptor, exhibiting an IC50 of 8.34 nM. This compound demonstrates broad-spectrum anti-HIV-1 activity and can be utilized in research focused on HIV pathogenesis and therapy development. Its mechanism of action makes it a valuable tool for studies aimed at blocking viral entry and understanding the role of CCR5 in immune response.

    Out of stock

    All 3 sizes
  • CMPD167
    Cat. No.
    A51621

    CMPD167

    Synonyms: MRK-1

    CMPD167 is a selective CCR5 inhibitor that exerts its antiviral effects by blocking the CCR5 receptor, which is critical for the entry of certain viruses into host cells. This compound demonstrates potent antiviral activity in vitro, making it a valuable tool for research on viral infections, particularly in studies related to HIV. CMPD167 can facilitate investigations into CCR5-related pathways and the development of therapeutic strategies targeting viral entry mechanisms.

    Out of stock

    All 3 sizes
  • CB-0821
    Cat. No.
    A51671

    CB-0821

    CB-0821 is a high-affinity CCR5 inhibitor with a Ki value of 0.04 nM. It effectively binds to the hydrophobic pocket of the CCR5 protein, disrupting the interactions between viral proteins and CCR5, which inhibits viral entry into cells. This compound is poised for use in anti-HIV research applications, facilitating studies on viral tropism and potential therapeutic strategies.

    5 mg
    $195.00
    10 mg
    $310.00
    All 5 sizes
  • E913
    Cat. No.
    A51737

    E913

    E913 is a selective antagonist of the CCR5 receptor, effectively inhibiting the binding of macrophage inflammatory protein-1alpha (MIP-1alpha) to CCR5 with an IC50 of 0.002 μM. This compound also blocks MIP-1alpha-induced cellular Ca2+ mobilization, demonstrating an IC50 of 0.02 μM. E913 significantly suppresses the replication of both laboratory and primary R5 HIV-1 strains, including multidrug-resistant variants, with IC50 values ranging from 0.03 to 0.06 μM. This reagent is valuable for research into HIV-1 infection and related mechanisms of immune response.

    Out of stock

    All 3 sizes
  • GSK-214096
    Cat. No.
    A51789

    GSK-214096

    GSK-214096 is a selective CCR5 antagonist that inhibits HIV-1 entry through the blockade of the virus's glycoprotein 120 (gp120). By targeting the CCR5 co-receptor, this compound plays a critical role in interrupting HIV-1 infection pathways. It is valuable for research applications focused on HIV-1 biology and therapeutic discovery.

    Out of stock

    All 3 sizes
  • SB-328437
    Cat. No.
    A53988

    SB-328437

    SB-328437 is a selective non-peptide antagonist of the CCR3 receptor, demonstrating an IC50 of 4.5 nM. This compound effectively inhibits eosinophil migration induced by eotaxin, eotaxin-2, and monocyte chemotactic protein-4, making it valuable in studies of allergic inflammation. Additionally, SB-328437 has shown the ability to sensitize 5-FU-resistant gastric cancer cells and reduce neutrophil recruitment to the lungs, thus mitigating pulmonary inflammation during acute inflammatory responses. Its applications extend to the investigation of various inflammation-related diseases.

    1 mg
    $30.00
    5 mg
    $65.00
    All 7 sizes
  • IDOR-1117-2520
    Cat. No.
    A59081

    IDOR-1117-2520

    IDOR-1117-2520 is a potent and selective reversible antagonist targeting CCR6. It effectively inhibits CCL20-mediated calcium influx with an IC50 of 63 nM and blocks β-arrestin recruitment to human CCR6, showing an IC50 of 30 nM in recombinant cell models. As a substrate of P-glycoprotein/MDR1, IDOR-1117-2520 is a valuable tool for investigating autoimmune diseases and skin inflammation in research settings.

    1 mg
    $160.00
    5 mg
    $410.00
    All 5 sizes
  • CCR6 antagonist 1
    Cat. No.
    A59500

    CCR6 antagonist 1

    CCR6 antagonist 1 is a selective antagonist of the CCR6 receptor, effectively inhibiting the CCL20/CCR6 signaling pathway. This compound is instrumental in research focusing on autoimmune-mediated inflammatory diseases, particularly inflammatory bowel diseases (IBDs). Its role in modulating the CCR6 axis provides insights into potential therapeutic strategies for managing such conditions.

    1 mg
    $25.00
    2 mg
    $35.00
    All 8 sizes
  • Abaucin
    Cat. No.
    A59501

    Abaucin

    Synonyms: RS102895; MLJS-21001

    Abaucin is a potent CCR2 antagonist, demonstrating an IC50 of 360 nM. It selectively inhibits CCR2 without affecting CCR1, making it a valuable tool for studying immunological responses and inflammatory processes. Abaucin is applicable in research focusing on the role of CCR2 in disease models and therapeutic interventions targeting chemokine receptors.

    2 mg
    $30.00
    5 mg
    $50.00
    All 6 sizes
  • CCR6 inhibitor 1
    Cat. No.
    A59502

    CCR6 inhibitor 1

    CCR6 Inhibitor 1 is a highly selective inhibitor of the CCR6 receptor, demonstrating IC50 values of 0.45 nM for monkey CCR6 and 6 nM for human CCR6, while exhibiting minimal activity against human CCR1 and CCR7. This inhibitor effectively prevents ERK phosphorylation, making it a valuable tool in the study of signaling pathways. CCR6 Inhibitor 1 is employed in research focused on autoimmune diseases and cancer, facilitating insights into therapeutic strategies targeting CCR6-related pathways.

    1 mg
    $95.00
    5 mg
    $245.00
    All 7 sizes
  • CCR7 Ligand 1
    Cat. No.
    A59503

    CCR7 Ligand 1

    Synonyms: CCR7-Cmp2105

    CCR7 Ligand 1 is a potent allosteric antagonist targeting the human CC chemokine receptor 7 (CCR7), with a dissociation constant (Kd) of 3 nM. This thiadiazole-dioxide compound effectively inhibits arrestin binding upon CCL19 activation, exhibiting an IC50 of 7.3 μM. CCR7 Ligand 1 is valuable for research applications focused on immune response modulation, chemokine signaling pathways, and therapeutic development for related conditions.

    2 mg
    $195.00
    5 mg
    $490.00
    All 5 sizes
  • Zelnecirnon
    Cat. No.
    A59504

    Zelnecirnon

    Synonyms: RPT193

    Zelnecirnon is an orally active CCR4 inhibitor that effectively blocks the recruitment of Th2 inflammatory immune cells to inflamed tissues. This compound exhibits potent anti-inflammatory activity, making it valuable in researching allergic inflammation associated with conditions such as atopic dermatitis and asthma. Zelnecirnon serves as a critical tool for understanding and developing therapeutic strategies in inflammatory diseases.

    5 mg
    $410.00
    10 mg
    $670.00
    All 5 sizes
  • J-113863
    Cat. No.
    A59505

    J-113863

    J-113863 is a potent and selective antagonist of the CCR1 receptor, demonstrating IC50 values of 0.9 nM and 5.8 nM for human and mouse CCR1, respectively. Additionally, it acts as a strong antagonist of the human CCR3 receptor (IC50 of 0.58 nM), while exhibiting weak antagonistic activity against mouse CCR3 (IC50 of 460 nM). J-113863 shows inactivity toward CCR2, CCR4, and CCR5, as well as LTB4 and TNF-α receptors. This compound is primarily utilized in anti-inflammatory research applications.

    1 mg
    $45.00
    2 mg
    $65.00
    All 7 sizes
  • C-021 dihydrochloride
    Cat. No.
    A59506

    C-021 dihydrochloride

    C-021 dihydrochloride is a highly effective antagonist of the CC chemokine receptor-4 (CCR4). It significantly inhibits chemotaxis in both human and mouse models, exhibiting IC50 values of 140 nM and 39 nM, respectively. Additionally, C-021 dihydrochloride demonstrates capability in preventing the binding of human CCL22-derived [35S]GTPγS to CCR4, with an IC50 of 18 nM. This compound is valuable for research applications focused on immune response modulation and related therapeutic strategies.

    1 mg
    $40.00
    5 mg
    $80.00
    All 5 sizes
  • PF-07054894
    Cat. No.
    A59507

    PF-07054894

    PF-07054894 is a potent and orally active antagonist of the C-C Chemokine Receptor 6 (CCR6), effectively blocking CCR6-mediated chemotaxis with an IC50 of 5.7 nM in vitro. As a target of G protein-coupled receptors (GPCRs), PF-07054894 demonstrates significant potential in the study of inflammatory bowel disease and related immunological disorders, providing a valuable tool for understanding CCR6’s role in inflammation.

    1 mg
    $480.00
    5 mg
    $1,230.00
    All 6 sizes
  • C-021
    Cat. No.
    A59508

    C-021

    C-021 is a potent antagonist of the CC chemokine receptor-4 (CCR4). It effectively inhibits functional chemotaxis in both human and mouse models, exhibiting IC50 values of 140 nM and 39 nM, respectively. Additionally, C-021 demonstrates strong efficacy in blocking the binding of human CCL22-derived [35S]GTPγS to CCR4, with an IC50 of 18 nM. This compound is valuable for research applications focused on immune response modulation and cancer biology.

    1 mg
    $40.00
    2 mg
    $55.00
    All 7 sizes
  • BI-6901
    Cat. No.
    A59509

    BI-6901

    BI-6901 is a potent and selective antagonist of the CCR10 receptor, exhibiting a pIC50 of 9.0. It demonstrates high selectivity among various GPCRs, including multiple chemokine receptors. BI-6901 has shown efficacy in the murine DNFB model of contact hypersensitivity, making it a valuable tool in inflammation research.

    1 mg
    $125.00
    5 mg
    $260.00
    All 6 sizes
  • INCB 3284
    Cat. No.
    A59510

    INCB 3284

    INCB 3284 is a selective and potent antagonist of the human CCR2 receptor, functioning by inhibiting the binding of monocyte chemoattractant protein-1 to hCCR2, with an IC50 value of 3.7 nM. This compound is of particular interest in studies related to acute liver failure, providing insights into the role of CCR2 signaling in inflammatory processes. Its oral bioavailability makes it a valuable tool for in vivo research applications.

    2 mg
    $25.00
    5 mg
    $40.00
    All 6 sizes
  • Tivumecirnon
    Cat. No.
    A59511

    Tivumecirnon

    Synonyms: FLX475

    Tivumecirnon is a selective CCR4 antagonist that functions by blocking the interaction of CCR4 with its ligands, CCL17 and CCL22. This mechanism reduces the infiltration of regulatory T cells (Tregs) into the tumor microenvironment, thereby enhancing antitumor activity. It is useful for research applications aimed at understanding immune modulation in cancer therapy.

    1 mg
    $135.00
    5 mg
    $350.00
    All 6 sizes
  • CCR2 antagonist 4 hydrochloride
    Cat. No.
    A59512

    CCR2 antagonist 4 hydrochloride

    Synonyms: Teijin compound 1 hydrochloride

    CCR2 antagonist 4 hydrochloride is a selective antagonist targeting the CCR2b receptor, exhibiting a potent inhibitory effect with an IC50 value of 180 nM. This compound effectively reduces MCP-1-induced chemotaxis, with an IC50 of 24 nM, making it a valuable tool for studying inflammatory pathways. Its application in research includes investigations into immune responses and the role of CCR2 in various disease models, particularly those related to monocyte migration and chronic inflammation.

    2 mg
    $45.00
    5 mg
    $90.00
    All 6 sizes
  • Ilacirnon
    Cat. No.
    A59513

    Ilacirnon

    Synonyms: CCX140; CCX140-B

    Ilacirnon is a potent CCR2 antagonist that specifically targets the C-C chemokine receptor type 2 (CCR2). This compound exhibits significant inhibitory activity, making it valuable in research focused on inflammatory diseases and immune response modulation. Ilacirnon can be utilized in studies exploring the role of CCR2 in various pathophysiological conditions, including atherosclerosis and chronic kidney disease.

    2 mg
    $40.00
    5 mg
    $50.00
    All 6 sizes
  • AZD-4818
    Cat. No.
    A59514

    AZD-4818

    AZD-4818 is a potent, orally active antagonist of the chemokine receptor CCR1. This compound selectively inhibits CCR1 signaling, making it a valuable tool for studying the role of this receptor in various inflammatory conditions. Applications include research into chronic obstructive pulmonary disease (COPD) and other related respiratory disorders.

    1 mg
    $30.00
    2 mg
    $50.00
    All 8 sizes
  • BMS CCR2 22
    Cat. No.
    A59515

    BMS CCR2 22

    BMS CCR2 22 is a potent antagonist of CC-type chemokine receptor 2 (CCR2), exhibiting a high binding affinity with an IC50 value of 5.1 nM. This compound demonstrates strong functional antagonism, as evidenced by its calcium flux IC50 of 18 nM and chemotaxis IC50 of 1 nM. BMS CCR2 22 is valuable for research applications targeting inflammatory responses and immune cell trafficking, providing insights into CCR2-related pathways.

    1 mg
    $40.00
    5 mg
    $95.00
    All 7 sizes
  • MK-0812 Succinate
    Cat. No.
    A59516

    MK-0812 Succinate

    MK-0812 Succinate is a potent and selective antagonist of the CCR2 receptor. It demonstrates high affinity for CCR2 and effectively inhibits its signaling pathway, making it a valuable tool for research into inflammatory and immune response processes. This compound is particularly relevant for studies focused on chronic pain, cardiovascular diseases, and various inflammatory disorders.

    1 mg
    $45.00
    5 mg
    $120.00
    All 4 sizes
  • Vercirnon sodium
    Cat. No.
    A59518

    Vercirnon sodium

    Synonyms: GSK-1605786 sodium; CCX282-B sodium; Traficet-EN sodium

    Vercirnon sodium is a potent and selective antagonist of CCR9, acting primarily by inhibiting CCR9-mediated Ca2+ mobilization and chemotaxis. This compound demonstrates significant biological activity, exhibiting IC50 values of 5.4 nM for Ca2+ mobilization and 3.4 nM for chemotaxis in Molt-4 cells. Vercirnon sodium shows high selectivity for CCR9, with IC50 values greater than 10 μM for other CCR and CX3CR subtypes. It effectively inhibits CCL25-directed chemotaxis in both CCR9 splice forms, CCR9A and CCR9B, with IC50 values of 2.8 nM and 2.6 nM, respectively, making it a valuable tool for research in inflammatory responses and related pathways.

    5 mg
    $270.00
    10 mg
    $435.00
    All 5 sizes

Items 51-75 of 154

Added to your cart

View Cart Checkout

    Loading...